Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03668119 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
A Phase 2 study of Pan Tumor, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
- 20
- Study locations
NCT03668119 is a Phase 2 study of Pan Tumor that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 212 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT03668119, a Phase 2 study of Pan Tumor, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Study Locations (20)
Other
- Local Institution - 0078 - CABA
- Local Institution - 0015 - CABA
- Local Institution - 0119 - Córdoba
- Local Institution - 0112 - Brussels
- Local Institution - 0113 - Brussels
Texas
- Local Institution - 0095 - Austin
- Local Institution - 0094 - Dallas
- Local Institution - 0090 - Houston
- Texas Oncology - Northeast Texas - Tyler
Buenos Aires
- Local Institution - 0016 - Ciudad Autonoma Beunos Aires
- Local Institution - 0087 - Ciudad Autónoma de Buenos Aires
New South Wales
- Local Institution - 0118 - St Leonards
- Local Institution - 0062 - Sydney
California
- John Wayne Cancer Center - Santa Monica
Colorado
- Rocky Mountain Cancer Centers - Denver
Minnesota
- Local Institution - 0093 - Minneapolis
New York
- Broome Oncology - Johnson City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2023-08-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03668119
The ClinicalTrials.gov registry entry for NCT03668119 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pan Tumor appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03668119 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Texas, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT03668119 about?
NCT03668119 is a clinical study titled "A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)". The purpose of this study is to demonstrate the clinical activity of nivolumab in combination with ipilimumab in multiple types of tumors based on their Tumor Mutational Burden status.
What is the current status of trial NCT03668119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2018-10-31. Estimated completion is 2023-08-02.
What conditions does trial NCT03668119 study?
This clinical trial studies the following conditions: Pan Tumor.
What interventions are being tested in trial NCT03668119?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03668119?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03668119 being conducted?
This trial has 20 study locations across California, Colorado, Minnesota, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.